BMY

Bristol-Myers Squibb Company

Healthcare · USD

BMY

Price

$58.34

+1.13%

Cap

$119.5B

Earnings

2/2 beat

30d Trend

+1%

BMY
Loading chart data...
0 data pointsPowered by Brain47
52-week range78%
42.5262.89

Upper half of range — momentum is positive

Analyst consensus (22 analysts)+6% to target
0 Strong Buy9 Buy12 Hold1 Sell0 Strong Sell

Target range: $37$85 (consensus: $61.59)

Consensus: Hold

Earnings history

Q4 2025

BEAT

1.26 vs 1.15

Q3 2025

BEAT

1.63 vs 1.48

VolatilityModerate

Key macro factors

·

US Consumer Inflation Expectations Rise, Led by Gas Prices: Rising inflation could lead to increased operating costs for Bristol Myers Squibb, including expenses for raw materials, manufacturing, and distribution. It could also indirectly impact consumer healthcare spending, potentially affecting patient adherence or demand for certain treatments if disposable incomes are strained.

·

US March Jobs Report Shows Mixed Labor Market Picture: A mixed or weakening labor market can influence consumer confidence and healthcare insurance coverage. A decrease in insured individuals or shifts in employer-sponsored health plans could affect Bristol Myers Squibb's sales volumes and the dynamics of pharmaceutical reimbursement.

·

OPEC+ Agrees Symbolic Production Hike Amid Supply Issues: Fluctuations in oil prices, even if influenced by symbolic production adjustments, can impact global supply chains and transportation costs for Bristol Myers Squibb. This could potentially lead to higher cost of goods sold and consequently affect the company's profitability.

Bristol-Myers Squibb Company is a global biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, distribution, and sale of innovative medicines for serious diseases in areas such as oncology, hematology, immunology, and cardiovascular health.

Next earnings:2026-04-30

QUANT SCORE

Building intelligence for this stock. Brain47 needs a few days of price data to calculate technical indicators and generate a full quant score.

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.

Bristol-Myers Squibb Company (BMY) — Brain47 AI Score 57/100 | Analysis